TY - JOUR T1 - Carvedilol reduced mortality and morbidity caused by myocardial infarction in patients with left ventricular dysfunction JF - Evidence Based Medicine JO - Evid Based Med SP - 15 LP - 15 DO - 10.1136/ebm.7.1.15 VL - 7 IS - 1 A2 - , Y1 - 2002/01/01 UR - http://ebm.bmj.com/content/7/1/15.abstract N2 - (2001) Lancet 357, 1385. The CAPRICORN Investigators.. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.. May 5;. :. –90.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In patients with left ventricular dysfunction, does adding carvedilol to the management of myocardial infarction (MI) reduce mortality and non-fatal MI? Randomised {allocation concealed*}†, blinded (patients, judicial assessors of outcomes, data analysts),* placebo controlled trial with a mean 1.3 years of follow up. 163 centres in 17 countries. 1959 patients (mean age 63 y, 74% men) participated. Inclusion criteria were age > 18 years; stable and definite MI occurring 3 to 21 days before randomisation; left ventricular ejection fraction ≤ 0.40; wall-motion-score index ≤ 1.3; current treatment with angiotensin-converting enzyme (ACE) inhibitors for ≥ 48 hours with a stable dose for ≥ 24 hours; and if the patient was having heart failure treatment with diuretics and … ER -